Federico Verde

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4300224/publications.pdf

Version: 2024-02-01

34 papers	1,842 citations	706676 14 h-index	466096 32 g-index
34 all docs	34 docs citations	34 times ranked	3655 citing authors

#	Article	IF	Citations
1	Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 68-74.	0.9	39
2	Upper motor neuron dysfunction is associated with the presence of behavioural impairment in patients with amyotrophic lateral sclerosis. European Journal of Neurology, 2022, 29, 1402-1409.	1.7	9
3	Tau proteins in blood as biomarkers of Alzheimerâ€™s disease and other proteinopathies. Journal of Neural Transmission, 2022, 129, 239-259.	1.4	8
4	Serum neurofilament light chain levels in Covid-19 patients without major neurological manifestations. Journal of Neurology, 2022, 269, 5691-5701.	1.8	16
5	Gaze-Contingent Eye-Tracking Training in Brain Disorders: A Systematic Review. Brain Sciences, 2022, 12, 931.	1.1	6
6	Next-generation sequencing application to investigate skeletal muscle channelopathies in a large cohort of Italian patients. Neuromuscular Disorders, 2021, 31, 336-347.	0.3	13
7	Cerebrospinal fluid phosphorylated neurofilament heavy chain and chitotriosidase in primary lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 221-223.	0.9	9
8	Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 276-286.	1.1	14
9	Association between renin-angiotensin-aldosterone system inhibitors and risk of dementia: A meta-analysis. Pharmacological Research, 2021, 166, 105515.	3.1	24
10	Neurofilament Light Chain as Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Frontiers in Neuroscience, 2021, 15, 679199.	1.4	66
11	Association of Clinically Evident Eye Movement Abnormalities With Motor and Cognitive Features in Patients With Motor Neuron Disorders. Neurology, 2021, 97, e1835-e1846.	1.5	11
12	Emotional Processing and Experience in Amyotrophic Lateral Sclerosis: A Systematic and Critical Review. Brain Sciences, 2021, 11, 1356.	1.1	6
13	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2021, 17, .	0.4	7
14	International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e047209.	0.4	1
15	PON1 is a disease modifier gene in amyotrophic lateral sclerosis: association of the Q192R polymorphism with bulbar onset and reduced survival. Neurological Sciences, 2019, 40, 1469-1473.	0.9	14
16	Neurochemical biomarkers in amyotrophic lateral sclerosis. Current Opinion in Neurology, 2019, 32, 747-757.	1.8	24
17	Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 157-164.	0.9	174
18	Chromogranin A levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Neurobiology of Aging, 2018, 67, 21-22.	1.5	6

#	Article	IF	Citations
19	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	3.8	517
20	Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology, 2018, 90, e22-e30.	1.5	148
21	Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 239-247.	0.9	89
22	ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase function. Neurobiology of Aging, 2018, 71, 266.e1-266.e10.	1.5	59
23	The multisystem degeneration amyotrophic lateral sclerosis - neuropathological staging and clinical translation. Archives Italiennes De Biologie, 2018, 155, 210-227.	0.1	12
24	Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis. Science Translational Medicine, 2017, 9, .	5.8	129
25	The role of de novo mutations in the development of amyotrophic lateral sclerosis. Human Mutation, 2017, 38, 1534-1541.	1.1	13
26	A novel nonsense ATP7A pathogenic variant in a family exhibiting a variable occipital horn syndrome phenotype. Molecular Genetics and Metabolism Reports, 2017, 13, 14-17.	0.4	7
27	MRI abnormalities found 1Âyear prior to symptom onset in a case of Creutzfeldtâ€“Jakob disease. Journal of Neurology, 2016, 263, 597-599.	1.8	11
28	NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1037-1042.	9.4	218
29	The validation of the Italian Edinburgh Cognitive and Behavioural ALS Screen (ECAS). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 489-498.	1.1	125
30	Amyotrophic Lateral Sclerosis: Epidemiology and Risk Factors. , 2016, , 219-230.		2
31	An old woman with pressure ulcer, rigidity, and opisthotonus: never forget tetanus!. Lancet, The, 2014, 384, 2266.	6.3	7
32	Oligoclonal bands in the cerebrospinal fluid of amyotrophic lateral sclerosis patients with disease-associated mutations. Journal of Neurology, 2013, 260, 85-92.	1.8	24
33	Analysis of hnRNPA1, A2/B1, and A3 genes in patients with amyotrophic lateral sclerosis. Neurobiology of Aging, 2013, 34, 2695.e11-2695.e12.	1.5	30
34	Genome-Wide Analyses Identify KIF5A as a Novel ALS Gene. SSRN Electronic Journal, 0, , .	0.4	4